Stockreport
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75 million public offering, extending cash runway into 2028Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025 NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025. “This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We are encouraged by the clinical responses observed in HNSCC and cervical cancer from a patient population that was heavily pre-treated with other therapies and look forward to
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CRBP | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CRBP alerts
CRBP alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
NEWS
NEWS
- While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership [Yahoo! Finance][Yahoo! Finance]
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript [Seeking Alpha][Seeking Alpha]
- Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by analysts at Royal Bank Of Canada from $55.00 to $53.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences[GlobeNewswire]
- Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window [Seeking Alpha][Seeking Alpha]
- More
CRBP
SEC Filings
SEC Filings
- 12/18/25 - Form 8-K
- 12/15/25 - Form SCHEDULE
- 12/15/25 - Form 4
- CRBP's page on the SEC website
- More